Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00301288
Status:
COMPLETED
Last Update Posted:
2010-01-12
First Post:
2006-03-09
Brief Title:
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma NHL
Sponsor:
Royal Marsden NHS Foundation Trust
Organization:
Royal Marsden NHS Foundation Trust
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with aggressive Non-Hodgkin-lymphoma treated at first diagnosis with chemotherapy alone or combined chemo-radiotherapy can achieve high response rates However patients with relapsed lymphoma still have a poor prognosis High dose chemotherapy HDCT followed by autologous stem cell transplantation ASCT is the treatment of choice for these patients An ASCT allows patients to receive much higher doses of chemotherapy than usual to improve the chances of curing the disease The high-dose of chemotherapy destroys the cells in the patients bone marrow and then the patients own cells from either the bone marrow or peripheral blood are used to rescue the patient from intensive treatment High-dose chemotherapy with autologous stem cell either bone marrow or peripheral blood transplantation is used in the treatment of IntermediateHigh grade NHL with poor risk disease and in second remission at the Royal Marsden Hospital
The purpose of the present analysis is to determine independent prognostic factors correlated with the long-term outcome of patients with NHL who received an ASCT between January 1991 and June 2005 Accrual of eligible patients currently under follow-up will be performed in clinic at the time of next appointment All patients accrued will give informed consent to participate in the study for retrospective case note review after discussion with a study investigator and after receiving a study information sheet The results of the analysis will be published in a peer-reviewed medical journal This will include patients treated at the royal Marsden Hospital only
The purpose of the present analysis is to determine independent prognostic factors correlated with the long-term outcome of patients with NHL who received an ASCT between January 1991 and June 2005 Accrual of eligible patients currently under follow-up will be performed in clinic at the time of next appointment All patients accrued will give informed consent to participate in the study for retrospective case note review after discussion with a study investigator and after receiving a study information sheet The results of the analysis will be published in a peer-reviewed medical journal This will include patients treated at the royal Marsden Hospital only
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None